BACKGROUND: The clinicopathologic significance of lower uterine segment involvement (LUSI) in endometrial cancer patients remains unclear. Although LUSI has been reported to be a prognostic indicator, literature is limited. METHODS: We studied 481 surgically staged endometrioid endometrial cancers with disease confined to the uterus (FIGO 1988 stage I or II). Primary outcomes were overall survival (OS) and disease-free survival (DFS). The relationships between LUSI and OS and DFS were assessed using the Kaplan-Meier method and Cox proportional hazard models. The t test or Fisher exact test was used for evaluating relationships between variables of interest. RESULTS: LUSI was present in 223 cases (46.4%), and was associated with both decreased disease free survival (P = 0.02) and overall survival (P = 0.01) in univariate analysis. Multivariate analysis confirmed the association between LUSI and increased risk for recurrence [hazard ratio (HR) 2.27; 95% confidence interval (95% CI) 1.09-4.7; P = 0.03] and increased mortality (HR 1.76; 95% CI 1.12-2.78; P = 0.01). CONCLUSIONS: LUSI in patients with early-stage endometrioid endometrial cancer is associated with decreased survival.
BACKGROUND: The clinicopathologic significance of lower uterine segment involvement (LUSI) in endometrial cancerpatients remains unclear. Although LUSI has been reported to be a prognostic indicator, literature is limited. METHODS: We studied 481 surgically staged endometrioid endometrial cancers with disease confined to the uterus (FIGO 1988 stage I or II). Primary outcomes were overall survival (OS) and disease-free survival (DFS). The relationships between LUSI and OS and DFS were assessed using the Kaplan-Meier method and Cox proportional hazard models. The t test or Fisher exact test was used for evaluating relationships between variables of interest. RESULTS:LUSI was present in 223 cases (46.4%), and was associated with both decreased disease free survival (P = 0.02) and overall survival (P = 0.01) in univariate analysis. Multivariate analysis confirmed the association between LUSI and increased risk for recurrence [hazard ratio (HR) 2.27; 95% confidence interval (95% CI) 1.09-4.7; P = 0.03] and increased mortality (HR 1.76; 95% CI 1.12-2.78; P = 0.01). CONCLUSIONS:LUSI in patients with early-stage endometrioid endometrial cancer is associated with decreased survival.
Authors: Justine M Briët; Harry Hollema; Nathalie Reesink; Jan G Aalders; Marian J E Mourits; Klaske A ten Hoor; Elisabeth Pras; H Marike Boezen; Ate G J van der Zee; Hans W Nijman Journal: Gynecol Oncol Date: 2005-03 Impact factor: 5.482
Authors: S Dilek; M Dede; K Gezginç; M C Yenen; U Göktolga; H C Ulutin; M S Deveci; E Erdemoglu; T Aydogdu Journal: Eur J Gynaecol Oncol Date: 2008 Impact factor: 0.196
Authors: O Gemer; M Gdalevich; M Voldarsky; F Barak; A Ben Arie; D Schneider; T Levy; E Y Anteby; O Lavie Journal: Eur J Surg Oncol Date: 2008-11-14 Impact factor: 4.424
Authors: O Lavie; L Uriev; M Gdalevich; F Barak; G Peer; R Auslender; E Anteby; O Gemer Journal: Int J Gynecol Cancer Date: 2007-12-13 Impact factor: 3.437
Authors: Shannon N Westin; Robin A Lacour; Diana L Urbauer; Rajyalakshmi Luthra; Diane C Bodurka; Karen H Lu; Russell R Broaddus Journal: J Clin Oncol Date: 2008-11-10 Impact factor: 44.544
Authors: Paweł Cisek; Dariusz Kieszko; Izabela Kordzińska-Cisek; Elżbieta Kutarska; Ludmiła Grzybowska-Szatkowska Journal: Biomed Res Int Date: 2018-02-21 Impact factor: 3.411